Oxford BioTherapeutics Takes Exclusive Rights to Use Xenomouse® Antibodies and ADC Technology

News   May 16, 2014

 
Oxford BioTherapeutics Takes Exclusive Rights to Use Xenomouse® Antibodies and ADC Technology
 
 
 
FURTHER INFORMATION
 

This content appears on:

Cancer Research Cell Science

To personalize the content you see on Technology Networks, Log In or Join Today

Login Join
 
 

Comments | 0 ADD COMMENT